Heymach J - Search Results

1

Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium.

Beaudry P, Nilsson M, Rioth M, Prox D, Poon D, Xu L, Zweidler-Mckay P, Ryan A, Folkman J, Ryeom S, Heymach J. Beaudry P, et al. Among authors: heymach j. Mol Cancer Ther. 2008 Feb;7(2):418-24. doi: 10.1158/1535-7163.MCT-07-0568. Epub 2008 Feb 1. Mol Cancer Ther. 2008. PMID: 18245671

2

Antiangiogenic therapy and p53.

Browder T, Folkman J, Hahnfeldt P, Heymach J, Hlatky L, Kieran M, Rogers MS. Browder T, et al. Among authors: heymach j. Science. 2002 Jul 26;297(5581):471; discussion 471. Science. 2002. PMID: 12143876 No abstract available.

3

Angiogenesis inhibitors and hypoxia.

Kieran MW, Folkman J, Heymach J. Kieran MW, et al. Among authors: heymach j. Nat Med. 2003 Sep;9(9):1104; author reply 1104-5. doi: 10.1038/nm0903-1104a. Nat Med. 2003. PMID: 12949515 No abstract available.

4

Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells.

Schuch G, Heymach JV, Nomi M, Machluf M, Force J, Atala A, Eder JP Jr, Folkman J, Soker S. Schuch G, et al. Among authors: heymach jv. Cancer Res. 2003 Dec 1;63(23):8345-50. Cancer Res. 2003. PMID: 14678995

5

Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.

Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD. Heymach JV, et al. Clin Cancer Res. 2004 Sep 1;10(17):5732-40. doi: 10.1158/1078-0432.CCR-04-0157. Clin Cancer Res. 2004. PMID: 15355900 Clinical Trial.

6

Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.

Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, Soker S, Johnson BE, Folkman J, Heymach JV. Beaudry P, et al. Among authors: heymach jv. Clin Cancer Res. 2005 May 1;11(9):3514-22. doi: 10.1158/1078-0432.CCR-04-2271. Clin Cancer Res. 2005. PMID: 15867254

7

ZD6474--clinical experience to date.

Heymach JV. Heymach JV. Br J Cancer. 2005 Jun;92 Suppl 1(Suppl 1):S14-20. doi: 10.1038/sj.bjc.6602604. Br J Cancer. 2005. PMID: 15928653 Free PMC article. Review.

8

Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve.

Celik I, Sürücü O, Dietz C, Heymach JV, Force J, Höschele I, Becker CM, Folkman J, Kisker O. Celik I, et al. Among authors: heymach jv. Cancer Res. 2005 Dec 1;65(23):11044-50. doi: 10.1158/0008-5472.CAN-05-2617. Cancer Res. 2005. PMID: 16322254

9

Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.

Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Heymach JV, et al. Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4441s-4445s. doi: 10.1158/1078-0432.CCR-06-0286. Clin Cancer Res. 2006. PMID: 16857825 Review.

10

Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis.

Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. Herbst RS, et al. Among authors: heymach jv. Expert Opin Investig Drugs. 2007 Feb;16(2):239-49. doi: 10.1517/13543784.16.2.239. Expert Opin Investig Drugs. 2007. PMID: 17243944 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

531 results

Search Page

Filters